Yung-Jue Bang

25PUBLICATIONS
134CO-AUTHORS
Molecular targetsEpidemiological methodsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Oct 04, 2024
INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.

Nick Pavlakis, Kohei Shitara, Katrin Sjoquist

|May 14, 2024
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial.

Kohei Shitara, Yung-Jue Bang, Satoru Iwasa

|Aug 30, 2023
Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens.

Josep Tabernero, Philippe L Bedard, Yung-Jue Bang

|Jul 31, 2023
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.

Manish A Shah, Kohei Shitara, Jaffer A Ajani

|Jul 25, 2023
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.

Samuel J Klempner, Keun-Wook Lee, Kohei Shitara

|Apr 14, 2023
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.

Vivek Subbiah, Robert J Kreitman, Zev A Wainberg

Pageof 5

Frequent Collaborators

7 joint publications

Kohei Shitara

5 joint publications

Keun-Wook Lee

4 joint publications

Chia-Chi Lin

3 joint publications

Josep Tabernero